` FEMY (Femasys Inc) vs S&P 500 Comparison - Alpha Spread

FEMY
vs
S&P 500

Over the past 12 months, FEMY has underperformed S&P 500, delivering a return of -6% compared to the S&P 500's 8% growth.

Stocks Performance
FEMY vs S&P 500

Loading
FEMY
S&P 500
Add Stock

Performance Gap
FEMY vs S&P 500

Loading
FEMY
S&P 500
Difference

Performance By Year
FEMY vs S&P 500

Loading
FEMY
S&P 500
Add Stock

Competitors Performance
Femasys Inc vs Peers

Femasys Inc
Glance View

Market Cap
32.6m USD
Industry
Health Care

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.

FEMY Intrinsic Value
2.29 USD
Undervaluation 48%
Intrinsic Value
Price
Back to Top